DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidcardiologytroponinbiomarkersACSmyocardial-injury

Cardiac biomarkers and troponin interpretation

Essential points for quick revision.

!
Escalate

Do not wait for troponin when the ECG shows STEMI or there is ongoing ischaemia, shock or a life-threatening arrhythmia; activate urgent reperfusion or senior assessment immediately.

Synopsis

Interpret high-sensitivity troponin as a time-dependent marker of myocardial injury and integrate it with symptoms, ECG and the assay-specific pathway.

  • Cardiac troponin above the assay's 99th-centile upper reference limit defines myocardial injury, not its cause.
  • Acute injury requires a rise or fall; myocardial infarction additionally requires clinical evidence of acute ischaemia.
  • Use the validated sampling times and thresholds for the exact high-sensitivity assay in your laboratory.

Key red flags

STEMI despite pending biomarkers

Persistent diagnostic ST elevation with a compatible presentation is a reperfusion diagnosis; troponin delay can cost myocardium.

Investigation priorities

01
Serial high-sensitivity cardiac troponinFirst step

Detect or exclude acute myocardial injury.

Management branches

Preferred routeSuspected NSTE-ACS

Compatible symptoms without diagnostic persistent ST elevation

  1. Obtain ECG and first high-sensitivity troponin promptly, documenting symptom-onset time.
  2. Apply the exact assay's validated early rule-out or serial algorithm; repeat ECG and troponin if indicated.
Open full textbook Answer 2 questionsCardiology check
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom